HK1049661B - 細胞周期蛋白依賴激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]酰胺抑制劑 - Google Patents

細胞周期蛋白依賴激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]酰胺抑制劑

Info

Publication number
HK1049661B
HK1049661B HK03100935.5A HK03100935A HK1049661B HK 1049661 B HK1049661 B HK 1049661B HK 03100935 A HK03100935 A HK 03100935A HK 1049661 B HK1049661 B HK 1049661B
Authority
HK
Hong Kong
Prior art keywords
oxazolyl
thiazolyl
thio
alkyl
methyl
Prior art date
Application number
HK03100935.5A
Other languages
English (en)
Other versions
HK1049661A1 (en
Inventor
N Misra Raj
Xiao Hai-Yun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,511 external-priority patent/US6262096B1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1049661A1 publication Critical patent/HK1049661A1/xx
Publication of HK1049661B publication Critical patent/HK1049661B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100935.5A 1999-12-15 2003-02-07 細胞周期蛋白依賴激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]酰胺抑制劑 HK1049661B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/464,511 US6262096B1 (en) 1997-11-12 1999-12-15 Aminothiazole inhibitors of cyclin dependent kinases
US61662700A 2000-07-26 2000-07-26
PCT/US2000/033501 WO2001044242A1 (en) 1999-12-15 2000-12-07 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases

Publications (2)

Publication Number Publication Date
HK1049661A1 HK1049661A1 (en) 2003-05-23
HK1049661B true HK1049661B (zh) 2005-10-07

Family

ID=27041008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100935.5A HK1049661B (zh) 1999-12-15 2003-02-07 細胞周期蛋白依賴激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]酰胺抑制劑

Country Status (29)

Country Link
EP (1) EP1240166B1 (zh)
JP (1) JP2003516987A (zh)
KR (1) KR100738132B1 (zh)
CN (1) CN1433416A (zh)
AR (1) AR026974A1 (zh)
AT (1) ATE289306T1 (zh)
AU (1) AU783719B2 (zh)
BR (1) BR0016424A (zh)
CA (1) CA2394552A1 (zh)
CO (1) CO5261565A1 (zh)
CZ (1) CZ20022015A3 (zh)
DE (1) DE60018205T2 (zh)
DK (1) DK1240166T3 (zh)
EG (1) EG24168A (zh)
ES (1) ES2236034T3 (zh)
HK (1) HK1049661B (zh)
HU (1) HUP0301032A3 (zh)
IL (2) IL149755A0 (zh)
MX (1) MXPA02005870A (zh)
MY (1) MY125768A (zh)
NO (1) NO323726B1 (zh)
NZ (1) NZ519120A (zh)
PE (1) PE20011026A1 (zh)
PL (1) PL364921A1 (zh)
PT (1) PT1240166E (zh)
RU (1) RU2002119016A (zh)
TW (1) TWI273103B (zh)
UY (1) UY26481A1 (zh)
WO (1) WO2001044242A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
CN100457753C (zh) * 2000-07-26 2009-02-04 布里斯托尔-迈尔斯斯奎布公司 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
MXPA03002299A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005605A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
NZ550883A (en) 2002-08-02 2008-06-30 Vertex Pharma Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3)
US7392929B1 (en) 2004-07-26 2008-07-01 Zephyros, Inc. Weldable synthetic material
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8236128B2 (en) 2006-10-26 2012-08-07 Zephyros, Inc. Adhesive materials, adhesive parts formed therewith and their uses
EP2089029B1 (en) * 2006-11-10 2012-10-03 Massachusetts Institute of Technology Pak inhibitors for use in treating neurodevelopmental disorders
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7028766B2 (ja) * 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
NO20022817D0 (no) 2002-06-13
PE20011026A1 (es) 2001-12-02
PT1240166E (pt) 2005-07-29
IL149755A (en) 2009-09-22
MY125768A (en) 2006-08-30
EP1240166B1 (en) 2005-02-16
RU2002119016A (ru) 2004-01-10
BR0016424A (pt) 2002-08-20
EP1240166A1 (en) 2002-09-18
KR20020067546A (ko) 2002-08-22
TWI273103B (en) 2007-02-11
DE60018205D1 (en) 2005-03-24
HK1049661A1 (en) 2003-05-23
AR026974A1 (es) 2003-03-05
CA2394552A1 (en) 2001-06-21
CN1433416A (zh) 2003-07-30
DE60018205T2 (de) 2006-02-16
CZ20022015A3 (cs) 2003-02-12
JP2003516987A (ja) 2003-05-20
WO2001044242A1 (en) 2001-06-21
HUP0301032A3 (en) 2009-03-30
PL364921A1 (en) 2004-12-27
MXPA02005870A (es) 2003-01-28
CO5261565A1 (es) 2003-03-31
NO20022817L (no) 2002-08-14
DK1240166T3 (da) 2005-06-20
WO2001044242A9 (en) 2001-11-08
UY26481A1 (es) 2001-07-31
ES2236034T3 (es) 2005-07-16
AU783719B2 (en) 2005-12-01
NZ519120A (en) 2004-03-26
IL149755A0 (en) 2002-12-01
KR100738132B1 (ko) 2007-07-10
NO323726B1 (no) 2007-07-02
ATE289306T1 (de) 2005-03-15
HUP0301032A2 (hu) 2003-08-28
AU2726401A (en) 2001-06-25
EG24168A (en) 2008-09-10

Similar Documents

Publication Publication Date Title
EG24409A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
HK1049661B (zh) 細胞周期蛋白依賴激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]酰胺抑制劑
PL364890A1 (en) Aminothiazole inhibitors of cyclin dependent kinases
HUP0300974A3 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use
EG24028A (en) Aminothiazole inhibitors of cyclin dependent kinases
EP1087951A4 (en) CARBON SUBSTITUTED AMINOTHIAZOLE, CYCLINE DEPENDENT KINASE INHIBITORS
LT2000033A (en) 4-aminothiazole derivatives as inhibitors of cyclin-dependent kinases
AP2001002298A0 (en) Inhibitors of impdh enzyme
PL355147A1 (en) 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors
AU2002213485A1 (en) Inhibitors of protein kinases
PL352282A1 (en) Derivatives of thiazoles and pharmaceutical compositions containing these derivatives
HK1039779A1 (zh) 用作旋轉異構酶抑制劑的雜環化合物
AU6111000A (en) Inhibitors of viral helcase
AU5553801A (en) Heterocycles that are inhibitors of impdh enzyme
AU2002350228A1 (en) Antisense modulation of myd88 expression
IL137929A0 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
GB0015904D0 (en) Inhibitors of HPV E1 helicase enzyme
AU2001259990A1 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
HK1081185A1 (en) Acyl derivatives of ziprasidone having neurolepticactivity
IL152792A0 (en) Heterocycle derivatives and methods of use
HUP0202819A3 (en) Process for the preparation of thiazole derivatives and the new intermediates
IS6696A (is) N-[5-[[[5-alkýl-2-oxazólýl]metýl]þíó]-2-þíazólýl]karboxamíð tálmar sýklínháðra kínasa
PL342284A1 (en) Method of obtaining heterocyclic inhibitors of 5-lipoxygenase
AU2002310077A1 (en) Thiazole compounds useful as inhibitors of protein kinases
GB9929309D0 (en) Semiochemical capable of effecting gene expression

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101207